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Objective: Rodent models have suggested that initial low-pressure reperfu-
sion of transplanted lungs reduces injury after ischemia. We investigated
this phenomenon and the use of pentoxifylline in a porcine model of left
single lung transplantation. Methods: Donor lungs were preserved with
Euro-Collins solution for a mean ischemic time of 18.4 hours. Neutrophil
trapping in the graft, pulmonary artery pressure, and gas exchange were
assessed over a 12-hour period. Partial occlusion of the contralateral
pulmonary artery allowed manipulation of the pulmonary artery pressure
in the transplanted lung. Group A (n 5 5) was perfused at a mean
pulmonary artery pressure of 20 mm Hg, group B was reperfused at a mean
pulmonary artery pressure of 45 mm Hg for 10 minutes before reducing the
pressure to the same as group A, and group C was reperfused at a mean
pressure of 20 mm Hg for 10 minutes, then increased to a mean of 45 mm
Hg for the remainder of the experiment. Group D was reperfused as in
group A with the addition of intravenous pentoxifylline. Results: Leukocyte
sequestration was observed in the first 10 minutes after reperfusion in
groups A, B, and C, with maximal sequestration at 2 minutes. Significantly
more sequestration was observed in the first 6 minutes in group B than in
groups A and C, which were similar. Pentoxifylline significantly reduced
leukocyte sequestration. Pulmonary venous oxygen tension in the allograft
lung was worst in group B. Groups A and C were similar, but group D was
superior to all other groups (p < 0.001). Conclusions: Low-pressure
reperfusion, even when limited to the first 10 minutes, modulates reperfu-
sion injury possibly through a leukocyte-dependent mechanism. The addi-
tion of pentoxifylline in the recipient confers significant additional benefit.
(J Thorac Cardiovasc Surg 1998;115:1335-41)
Despite advances in lung preservation technology,early graft dysfunction remains a significant
problem, affecting up to 20% of lung transplant
recipients worldwide.1, 2
Lung graft ischemia-reperfusion injury is complex
and multifactorial but is principally determined by
the sequestration of activated neutrophils within the
lung on reperfusion with subsequent release of
injurious granular enzymes and oxygen free radi-
cals.3
Controlled-pressure reperfusion of the graft has
been suggested as a potential strategy for attenuat-
ing acute pulmonary dysfunction. This involves the
reperfusion of a lung graft at 50% of physiologic
pressure for 10 minutes before reperfusion at phys-
iologic pressure.4, 5 Bhabra and colleagues4 showed
beneficial effects in an isolated rodent lung model,
but its inherent limitations prompted us to investi-
gate the phenomenon in more depth and to evaluate
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it in conjunction with pentoxifylline administration,
which has been successful in ameliorating reper-
fusion injury after skeletal muscle ischemia and
experimental lung and liver transplantation.6-8
Furthermore, although controlled-pressure reper-
fusion has been demonstrated at physiologic pres-
sures, we wished to investigate whether the ben-
efits remained when supranormal pressures were
applied— conditions more common in clinical
lung transplantation.
Methods
Twenty female Landrace pigs (mean weight 45.2 kg)
were divided into four groups (n 5 5 in each). A similar
number were size and weight matched and acted as donor
animals.
Group A animals (n 5 5) were perfused at a mean
pulmonary artery pressure (PAP) of 20 mm Hg through-
out the 12-hour experiment; group B animals were reper-
fused at a mean PAP of 45 mm Hg for 10 minutes before
reducing the pressure to the same as group A for the
remainder of the time course; and group C animals were
reperfused at a mean pressure of 20 mm Hg for 10
minutes, then increased to a mean of 45 mm Hg. Group D
animals were reperfused as in group A with the addition
of intravenous pentoxifylline administered to the recipient
animal only (20 mg/kg loading dose, then 2 mg/kg per
hour) beginning 5 minutes before reperfusion.
All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated
by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Science and pub-
lished by the National Institutes of Health (NIH publica-
tion 85-23, revised 1985). All conditions associated with
the United Kingdom Animals (Scientific Procedures) Act
1986 were also met.
Donor operation. Animals were anesthetized with ini-
tial intramuscular premedication with diazepam (2 mg/kg)
and ketamine (15 mg/kg). Subsequent anesthesia was
induced with propofol (20 mg/kg) and maintained with
isoflurane and intravenous alfentanil. Animals were intu-
bated with an endotracheal tube (outside diameter 9.5
mm) and ventilated at a tidal volume of 15 ml/kg at an
inspired oxygen concentration of 100%. Cannulas (Cava-
fix Certo 18G, Braun, Melsungen, Germany) were in-
serted into the external jugular vein and common carotid
artery for monitoring of central venous pressure and
arterial pressure, respectively.
After median sternotomy, the superior and inferior
venae cavae, main pulmonary artery (PA), trachea, and
ascending aorta were isolated. Animals were then given
heparin (300 U/kg), 10 mg/kg methylprednisolone, and a
cannula (model 145016, Polystan, Walgerholm, Denmark)
Fig. 1. Neutrophil sequestration in the lung graft with time. The number of neutrophils exiting the lung
is expressed as a percentage of the number of neutrophils entering the lung. A figure less than 100%
therefore indicates neutrophil trapping in the graft, whereas points more than 100% show neutrophil
release from the lung graft.
The Journal of Thoracic and
Cardiovascular Surgery
June 1998
1 3 3 6 Clark et al.
was inserted through a purse-string suture in the main PA.
Ligation of the cavae and venting of the right side of the
heart by incision of the inferior vena cava was followed by
crossclamping of the aorta. A 60 ml/kg dose of cold (4° C)
modified Euro-Collins solution was infused through the
cannula in the main PA, and the left side of the heart was
vented by incision of the left atrial appendage.
After topical cooling with saline solution (1° C), the
trachea was clamped at end-inspiration and the heart-lung
block excised.
After subsequent separation of the left lung from the
block, a PAP monitoring line (Cavafix Certo 18G, Braun,
Melsungen, Germany) was inserted through a purse-string
suture into the distal left PA. A pulmonary venous
sampling line (Flocare, Nutricia, Madrid, Spain) was
similarly placed through the left atrial cuff directed into a
distal pulmonary vein, allowing for later sampling of
venous blood from the graft without mixing from the
contralateral native lung after transplantation and reper-
fusion.
Recipient operation. Recipient animals were premedi-
cated with intramuscular azaperone (8 mg/kg) and diaze-
pam (2 mg/kg). After induction of anesthesia with intra-
venous propofol, animals were maintained on intravenous
pentobarbital (30 mg/kg per hour) and alfentanil. Venous
and arterial pressure monitoring lines were inserted as in
donor animals.
Two endotracheal tubes were inserted through a tra-
cheostomy. A 9.5 mm outside diameter tube was placed
into the trachea to ventilate both lungs initially and
subsequently the native lung alone. The second 6.5 mm
tube was advanced through the left bronchial anastomosis
after its completion to ventilate the graft lung indepen-
dently. Each endotracheal tube was connected to a sepa-
rate ventilator to permit individual asynchronous ventila-
tion after the transplant.
A left thoracotomy was performed followed by left
pneumonectomy. Implantation of the donor lung pro-
ceeded in an established fashion constructing anastomo-
ses of the left atrium, bronchus, and left PA in order. The
contralateral PA was encircled by a tape and snugger such
that the left PAP could be manipulated. A pressure
monitoring line was placed in the recipient left atrium,
and a dedicated sampling line was inserted into the
proximal left PA.
PA flow was acquired through a 10 mm Transonic
A-Series flow probe (Linton Instruments, Norfolk, United
Kingdom) placed around the left PA distal to the anasto-
motic line. A similar 12 mm probe was placed around the
descending aorta to provide a guide to the cardiac output.
Both flow probes were connected to a dual-channel
HT207 Medical volume flowmeter (Transonic Systems
Inc., Ithaca, N.Y.).
All the above pressure and flow data sources were
routed through a CED 1401 32-channel digital-to-analog
converter (Cambridge Electronic Design Ltd., Cambs,
United Kingdom) and acquired on a Gateway 2000 PC
running Microsoft Windows ‘95 and Spike 2 (Version 4.0)
Fig. 2. MDA (oxygen free radical marker) with time after reperfusion.
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data acquisition software (Cambridge Electronic Design
Ltd.). Data were stored continually over the 12-hour
postoperative period on hard disk for subsequent analysis.
Pulmonary venous oxygen partial pressure was obtained
from pulmonary venous sampling line samples analyzed
immediately on a blood gas analyzer (Nova Biomedical
Stat Profile 5, Waltham, Mass.).
Pulmonary vascular resistance (in millimeters of mer-
cury per liter per minute) was calculated from the formula
(Mean PAP [mm Hg] – Left atrial pressure [mm Hg])/Left
PA flow [L/min].
Neutrophil trapping within the lung was calculated by
expressing the neutrophil count of blood exiting the lung
as a percentage of that entering the lung at each sampling
interval.
Malonaldehyde (MDA), an important decomposition
product of lipid peroxides, is an indirect measure of free
radical activity.
A spectrophotometric assay using an LPO-586
method was used to quantify MDA in pulmonary
venous blood. Condensation of one molecule of MDA
with two molecules of a proprietary chromogenic agent
produces a stable chromophore with maximal absor-
bance at 586 nm.
Five milliliter samples of whole blood were collected in
48 ml of potassium ethylenediaminetetraacetic acid 0.17
mol/L. After centrifugation at 2500g for 10 minutes at
4° C, 200 ml of the supernatant was collected in duplicate
for use in the assay.
The sample was incubated for 40 minutes at 45° C with
the chromogenic substance, then cooled on ice, and
absorbance measured by spectrophotometer at 586 nm.
The sensitivity of this method was determined as 0.5
mmol/L. In samples of 200 ml, the lower limit of measur-
able MDA was 2.5 mmol/L. Reproducibility was deter-
mined by assays done over 10 days under identical exper-
imental conditions. With standard concentrations from 0
to 20 mmol/L, standard error of the mean was less than
5%.
Statistical methods. The summary measure of area
under the curve was used to describe the behavior of
individual animals.9 Groups of animals were then com-
pared by use of Scheffe analysis of variance, with p , 0.05
indicating statistical significance at a power of 90%. We
acknowledge the assistance of Dr. H. R. Matthews, Senior
Lecturer in Medical Statistics at the University of New-
castle-upon-Tyne, for his advice regarding the statistical
analysis of these data.
Results
Leukocyte sequestration in the lung graft was
observed in the first 10 minutes after reperfusion
(Fig. 1) in groups A, B, and C, with maximal
sequestration occurring at 2 minutes. After a pla-
teau phase lasting to 240 minutes after reperfusion,
neutrophils were released from the lung. In group D
Fig. 3. Pulmonary venous oxygen partial pressure in the graft lung with time.
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the administration of pentoxifylline abolished this
biphasic pattern of sequestration and subsequent
release.
Analysis of variance showed that overall neutro-
phil trapping in the graft was significantly reduced in
group D (p 5 0.029) compared with the other
groups. No differences in neutrophil sequestration
were observed in the other groups overall. However,
analysis of the first 30 minutes indicated significantly
more leukocyte sequestration in group B, reper-
fused at high pressure, than in groups A and D (p 5
0.001).
MDA levels were also significantly higher in lungs
reperfused at high pressure (p , 0.0001), whereas
those in groups A and C were similar (p 5 0.30).
Lungs in the pentoxifylline treatment group showed
significantly lower free radical levels than those in
the other groups (p , 0.0001) (Fig. 2).
Pulmonary venous oxygen tension in the allograft
lung was worst in group B (p , 0.001). Groups A
and C were similar (p 5 0.14), but group D, treated
with pentoxifylline, was superior to all other groups
(p , 0.0001) (Fig. 3). Some deterioration in function
was noted 9 hours after reperfusion in lungs reper-
fused at low pressure for an initial period of 10
minutes only compared with low-pressure reperfu-
sion throughout the 12-hour follow-up period.
Pulmonary vascular resistance was lowest in the
pentoxifylline-treated group (Fig. 4). Groups A and
C were statistically similar, but group B, reperfused
at high pressure, initially showed the highest pulmo-
nary vascular resistance and lowest graft flows over
the 12-hour study period.
Discussion
The original work on controlled-pressure reper-
fusion in isolated rat lungs suggested benefits in
terms of better oxygenation when lungs were reper-
fused at 50% of physiologic pressure for 10 minutes
before reperfusion at physiologic pressure.4, 5
These studies, however, are limited by the inher-
ent limitations of small animal models, the short
perfusion time of just 60 minutes, and the presence
of an extracorporeal circuit, which activates neutro-
phils and may influence pulmonary graft function.
Clearly, this strategy needed to be investigated in
Fig. 4. Pulmonary vascular resistance of the transplanted lung with time.
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a large animal model, enabling in vivo techniques of
implantation, longer (12-hour) reperfusion times,
and by allowing more substantive analysis to achieve
some insight into the mechanism.
Our model of left single lung transplantation
provides a stable and reproducible model, allowing
fine control of ventilation and perfusion of the lung
graft while the animal is supported by the contralat-
eral lung irrespective of the function in the newly
implanted graft. The rigorous separation of the
lungs in terms of sample collection ensures that
there is no mixing of blood from the contralateral
side.
The original rat model described controlled
reperfusion at physiologic pressure. This is rarely
encountered during clinical lung transplantation,
when pressures may approach systemic levels. It was
important to establish, therefore, whether con-
trolled-pressure reperfusion would still provide ben-
efit under supraphysiologic conditions. The use of a
high-pressure reperfusion group at an initial PAP of
45 mm Hg, with low-pressure groups being physio-
logic (20 mm Hg), indicated that this is indeed the
case.
Our experiments have also determined that low-
pressure reperfusion, even when limited to the first
10 minutes, modulates reperfusion injury. Our por-
cine model has established that the phenomenon
can be reproduced in a large animal model and that
the benefits of low-pressure reperfusion over high-
pressure reperfusion persist for as long as 12 hours.
Our data on reperfusion for a limited 10-minute
period suggest that benefit is similar to those lungs
reperfused at low pressure throughout, although by
9 hours after reperfusion the pulmonary venous
oxygen tension began to decline. The long-term
functional results of a limited period of perfusion at
low pressure has yet to be determined.
The mechanism behind controlled-pressure
reperfusion may involve the recovery of endothelial
integrity, possibly through prostacyclin or nitric ox-
ide pathways, or may modulate shear stresses known
to influence adhesion molecule expression and cy-
tokine release. Our data have indicated that less
neutrophil trapping occurs under conditions of low-
pressure reperfusion, even when limited to the first
10 minutes, with lower levels of oxygen free radical
release. Some studies have suggested that con-
trolled-pressure reperfusion acts through a purely
mechanical mechanism by ameliorating the shed-
ding of pulmonary vascular endothelium with rapid
reperfusion. Our studies indicate that the active
involvement of neutrophils is also important in the
process.
The addition of pentoxifylline in the recipient
confers significant additional benefit. Pentoxifylline
has many functions, in particular inhibiting the
adherence of neutrophils to endothelium and pre-
venting leukocyte degranulation. Pentoxifylline may
also inhibit the important interleukin, interleukin-1,
and tumor necrosis factor, which are critical in the
pathogenesis of ischemia-reperfusion injury.10, 11
Although pentoxifylline clearly improves and aug-
ments function in conjunction with low-pressure
reperfusion by reducing neutrophil trapping in the
lung and subsequent free radical release, any bene-
fits attained through its combination with high-
pressure reperfusion remain to be seen.
Our experiments administered pentoxifylline to
recipient animals only and has been beneficial using
this regimen in previous porcine models.12 There
has been some suggestion that pentoxifylline is
effective when administered in flush solutions but
not in the recipient alone.13 Our findings seem to
support the former, although results are difficult to
compare between different dose regimens and mod-
els.
These simple methods of controlled-pressure
reperfusion and pentoxifylline administration can be
instituted easily in the operating theater in human
recipients. Pentoxifylline (already licensed for use in
human beings with peripheral vascular disease) is an
inexpensive and safe drug for use in lung transplant
recipients. We now hope to begin a clinical trial of
these techniques to determine whether the benefits
observed in this porcine model are true in clinical
practice, which may lead to considerable improve-
ments in mortality and morbidity among lung trans-
plant recipients, as well as shorter intensive care
stays and costs.
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